JP2017171685A5 - - Google Patents

Download PDF

Info

Publication number
JP2017171685A5
JP2017171685A5 JP2017125081A JP2017125081A JP2017171685A5 JP 2017171685 A5 JP2017171685 A5 JP 2017171685A5 JP 2017125081 A JP2017125081 A JP 2017125081A JP 2017125081 A JP2017125081 A JP 2017125081A JP 2017171685 A5 JP2017171685 A5 JP 2017171685A5
Authority
JP
Japan
Prior art keywords
composition
solid tumor
composition according
peg
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017125081A
Other languages
English (en)
Japanese (ja)
Other versions
JP6440776B2 (ja
JP2017171685A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017171685A publication Critical patent/JP2017171685A/ja
Publication of JP2017171685A5 publication Critical patent/JP2017171685A5/ja
Application granted granted Critical
Publication of JP6440776B2 publication Critical patent/JP6440776B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017125081A 2006-09-28 2017-06-27 癌を処置するためのペグ化il−10の使用 Active JP6440776B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84832606P 2006-09-28 2006-09-28
US60/848,326 2006-09-28
US91560307P 2007-05-02 2007-05-02
US60/915,603 2007-05-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014250391A Division JP6169066B2 (ja) 2006-09-28 2014-12-10 癌を処置するためのペグ化il−10の使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018217411A Division JP6718494B2 (ja) 2006-09-28 2018-11-20 癌を処置するためのペグ化il−10の使用

Publications (3)

Publication Number Publication Date
JP2017171685A JP2017171685A (ja) 2017-09-28
JP2017171685A5 true JP2017171685A5 (https=) 2018-01-18
JP6440776B2 JP6440776B2 (ja) 2018-12-19

Family

ID=39304838

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2009530418A Active JP5105554B2 (ja) 2006-09-28 2007-09-27 癌を処置するためのペグ化il−10の使用
JP2012175219A Active JP5666523B2 (ja) 2006-09-28 2012-08-07 癌を処置するためのペグ化il−10の使用
JP2014250391A Active JP6169066B2 (ja) 2006-09-28 2014-12-10 癌を処置するためのペグ化il−10の使用
JP2017125081A Active JP6440776B2 (ja) 2006-09-28 2017-06-27 癌を処置するためのペグ化il−10の使用
JP2018217411A Active JP6718494B2 (ja) 2006-09-28 2018-11-20 癌を処置するためのペグ化il−10の使用

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2009530418A Active JP5105554B2 (ja) 2006-09-28 2007-09-27 癌を処置するためのペグ化il−10の使用
JP2012175219A Active JP5666523B2 (ja) 2006-09-28 2012-08-07 癌を処置するためのペグ化il−10の使用
JP2014250391A Active JP6169066B2 (ja) 2006-09-28 2014-12-10 癌を処置するためのペグ化il−10の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018217411A Active JP6718494B2 (ja) 2006-09-28 2018-11-20 癌を処置するためのペグ化il−10の使用

Country Status (12)

Country Link
US (6) US20080081031A1 (https=)
EP (3) EP2468293B1 (https=)
JP (5) JP5105554B2 (https=)
CN (1) CN101631560B (https=)
AU (1) AU2007314501B2 (https=)
BR (1) BRPI0719446A2 (https=)
CA (1) CA2664304C (https=)
ES (1) ES2606034T3 (https=)
MX (1) MX2009003362A (https=)
NO (1) NO346530B1 (https=)
NZ (1) NZ597098A (https=)
WO (1) WO2008054585A2 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7052686B2 (en) 2000-09-29 2006-05-30 Schering Corporation Pegylated interleukin-10
CA2664304C (en) * 2006-09-28 2017-08-22 Schering Corporation Use of pegylated il-10 to treat cancer
EP3348281B1 (en) * 2008-12-17 2023-07-05 Merck Sharp & Dohme Corp. Mono- and di-peg il-10 production; and uses
ES2891564T3 (es) 2010-04-01 2022-01-28 Oncorena Ab Tratamiento mejorado del carcinoma de células renales
MX2013012337A (es) * 2011-04-27 2014-04-16 Univ Northshore Healthsystem Composiciones y metodos.
CN104245722A (zh) * 2012-02-29 2014-12-24 Ambrx公司 白细胞介素-10多肽结合物和其用途
EP2986306A4 (en) * 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
ES2688206T3 (es) 2013-06-17 2018-10-31 Armo Biosciences, Inc. Procedimiento de evaluación de la identidad y la estabilidad de proteínas
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
EP3068425B1 (en) 2013-11-11 2021-01-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2015108785A1 (en) * 2014-01-15 2015-07-23 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
EP2896400A1 (en) * 2014-01-17 2015-07-22 Université Catholique De Louvain Method for increasing the bioavailability of inhaled compounds
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
WO2016060996A2 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US9808011B2 (en) 2014-12-15 2017-11-07 Biovectra Inc. Pentacyclic triterpene compounds and uses thereof
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
CA2986755A1 (en) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
US10398761B2 (en) 2015-08-25 2019-09-03 Armo Biosciences, Inc. Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers
CA3008284A1 (en) * 2016-01-05 2017-07-13 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
MX2018007295A (es) 2016-01-11 2019-03-28 Armo Biosciences Inc Interleucina 10 en la produccion de linfocitos t cd8+especificos para el antigeno y metodos de uso de estos.
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
TWI780046B (zh) 2016-05-10 2022-10-11 國立大學法人東京醫科齒科大學 炎症促進因子表現抑制劑、其有效成分之篩選方法、對於該方法為有用之表現匣、診斷藥及診斷方法
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
EP3600414A1 (en) 2017-03-30 2020-02-05 Progenity Inc. Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
SG11202004097RA (en) * 2017-11-09 2020-06-29 Univ Nat Corp Tokyo Medical & Dental Inhibitor of the expression of cancer-promoting factors, screening method for active ingredient thereof, expression cassette useful in said method, diagnostic drug, and diagnostic method
CA3079844A1 (en) 2017-11-10 2019-05-16 Armo Biosciences, Inc. Compositions and methods of use of interleukin-10 in combination with immune checkpoint pathway inhibitors
CN112533629A (zh) * 2018-06-19 2021-03-19 阿尔莫生物科技股份有限公司 结合使用il-10药剂与嵌合抗原受体细胞疗法的组合物和方法
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
US11084857B2 (en) 2018-12-05 2021-08-10 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Nsp-interleukin-10 proteins and uses thereof
BR102019007044A2 (pt) 2019-04-05 2021-12-28 Universidade Federal de Uberlândia Peptídeos sintéticos com afinidade ao receptor de interleucina-10, composição farmacêutica e uso dos mesmos como imunomuduladores no tratamento de doenças autoimunes, inflamatórias ou alérgicas
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
WO2022150788A2 (en) 2021-01-11 2022-07-14 Synthekine, Inc. Compositions and methods related to receptor pairing
US20240190934A1 (en) * 2022-11-28 2024-06-13 Elixiron Immunotherapeutics (hong Kong) Limited Engineered interleukin-10 and fusion proteins thereof

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US5714585A (en) 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
US5032396A (en) 1989-02-17 1991-07-16 Immunex Corporation IL-7 to stimulate platelet production
US5231012A (en) 1989-06-28 1993-07-27 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10)
US6217857B1 (en) 1989-06-28 2001-04-17 Schering Corporation Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof
US5229115A (en) 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
MY108267A (en) 1991-01-16 1996-09-30 Schering Corp Use of interleukin-10 in adoptive immunotherapy of cancer
JP3260368B2 (ja) * 1991-01-16 2002-02-25 シェリング・コーポレーション インターロイキン−10による腫瘍性疾患の処置
US5571702A (en) 1991-03-29 1996-11-05 Genentech, Inc. Amplification method for detection of human PF4A receptors
US5624823A (en) * 1991-11-22 1997-04-29 The General Hospital Corporation DNA encoding procine interleukin-10
MY111402A (en) * 1992-08-20 2000-04-29 Schering Corp Novel uses of il-4 and/or il-10, and antibodies against the same
US5552303A (en) 1993-03-08 1996-09-03 Immunex Corporation DNA encoding epithelium-derived T-cell factor
WO1994022473A1 (en) 1993-04-01 1994-10-13 University Of Washington Use of interleukin 7 to improve vaccine potency
US5665345A (en) * 1993-05-24 1997-09-09 The United States Of America As Represented By The Department Of Health And Human Services Methods of inhibiting viral replication using IL-10
FI960353A7 (fi) 1993-07-26 1996-01-26 Schering Corp Ihmisen interleukiini-10:n agonistit ja antagonistit
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
FI962813A0 (fi) * 1994-01-20 1996-07-11 Schering Corp IL-10:n käyttö perifeerisen veren yksitumaisten solujen sytolyyttisen aktiivisuuden stimuloimiseen
US5696234A (en) 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6410008B1 (en) * 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5866134A (en) * 1995-03-24 1999-02-02 Schering Corporation Method for enhancing the antibody response to specific antigens with Interleukin-10
NZ312532A (en) * 1995-07-14 2000-06-23 Schering Corp Treatment of acute leukemia with interleukin-10
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
US5888530A (en) 1995-07-21 1999-03-30 The General Hospital Corporation Method of enhancing delivery of a pharmaceutical formulation
GB2304047A (en) * 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
US5759859A (en) 1996-07-15 1998-06-02 United States Of America As Represented By The Secretary Of The Army Sensor and method for detecting trace underground energetic materials
US5989867A (en) * 1996-09-23 1999-11-23 Knappe; Andrea DNA encoding IL-10-like homologue; related reagents
US6660258B1 (en) * 1997-05-09 2003-12-09 Pharma Pacific Pty Ltd Oromucosal cytokine compositions and uses thereof
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
JP3786832B2 (ja) 1998-01-07 2006-06-14 デビオ ルシェルシュ ファルマシュティーク ソシエテ アノニム 分解性のヘテロ二官能性ポリ(エチレングリコール)アクリレート及びそれから誘導されるゲル及び複合体
US6326482B1 (en) 1999-04-23 2001-12-04 Genentech, Inc. SH2 domain-containing peptides
AU5827000A (en) * 1999-07-16 2001-02-05 Maria Teresa Bejarano Viral il-10 uses
US6989377B2 (en) * 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
US20030186386A1 (en) * 2000-02-11 2003-10-02 Hansen Christian Karsten Interleukin 10
CN1981868A (zh) * 2000-03-31 2007-06-20 拜奥根Idec公司 抗细胞因子抗体或拮抗剂与抗-cd20在b细胞淋巴瘤治疗中的联合应用
US7052686B2 (en) * 2000-09-29 2006-05-30 Schering Corporation Pegylated interleukin-10
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
AU2002307497A1 (en) 2001-04-23 2002-11-05 The Regents Of The University Of California Methods of using interleukin-7 to modulate physiological processes in mammalian pulmonary fibroblasts
GB0212648D0 (en) * 2002-05-31 2002-07-10 Immunoclin Lab Ltd Treatment with cytokines
EP1391513A1 (en) 2002-08-08 2004-02-25 Cytheris IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof
DE60332358D1 (de) 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
WO2004044006A1 (en) 2002-11-14 2004-05-27 Maxygen, Inc. Conjugates of interleukin-10 and polymers
AU2003292137A1 (en) * 2002-11-29 2004-06-23 Maria Grazia Roncarolo Rapamycin and il-10 for the treatment of immune diseases
NZ541122A (en) * 2002-12-26 2008-09-26 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
ATE459647T1 (de) 2003-04-15 2010-03-15 Glaxosmithkline Llc Humane il-18 substitutionsmutanten und deren konjugate
US7261882B2 (en) * 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
WO2005033307A1 (ja) 2003-09-30 2005-04-14 Kyowa Hakko Kogyo Co., Ltd. 新規のリフォールディング方法およびその方法によって得られたタンパク質
CA2551915C (en) 2003-12-30 2015-06-23 Merck Patent Gesellschaft Mit Beschraenkter Haftung Il-7 fusion proteins
JP5650367B2 (ja) * 2004-02-27 2015-01-07 アンティセンス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物
US20060046961A1 (en) * 2004-09-02 2006-03-02 Mckay William F Controlled and directed local delivery of anti-inflammatory compositions
CN101072793B (zh) 2004-12-09 2012-06-20 默克专利有限公司 具有降低的免疫原性的il-7变体
WO2006094530A1 (en) 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
WO2006119170A2 (en) * 2005-05-02 2006-11-09 Avigen, Inc. Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease
JP4992025B2 (ja) * 2005-05-31 2012-08-08 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイト 変異体il−10
EP1746161A1 (en) 2005-07-20 2007-01-24 Cytheris Glycosylated IL-7, preparation and uses
US7939056B2 (en) * 2005-11-14 2011-05-10 The Brigham And Women's Hospital, Inc. Interleukin-10 compositions for the treatment of adenocarcinomas
CA2664304C (en) * 2006-09-28 2017-08-22 Schering Corporation Use of pegylated il-10 to treat cancer
US20100068147A1 (en) * 2006-10-05 2010-03-18 Agency for Science , Technology and Research Dengue diagnosis and treatment
CA2708004C (en) * 2006-12-04 2015-12-01 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
US9550827B2 (en) * 2007-10-19 2017-01-24 The Regents Of The University Of California Methods for ameliorating and preventing central nervous system inflammation
SG186302A1 (en) 2010-06-16 2013-02-28 Abbott Lab Comparison of protein samples
US8759617B2 (en) 2010-09-21 2014-06-24 National Institute Of Agrobiological Sciences Method for extraction and purification of recombinant proteins from transgenic plants
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
MA41957A (fr) 2015-03-11 2018-02-28 Nektar Therapeutics Conjugués d'une fraction d'il-7 et d'un polymère

Similar Documents

Publication Publication Date Title
JP2017171685A5 (https=)
Araste et al. Peptide-based targeted therapeutics: Focus on cancer treatment
Dos Santos et al. Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents
Kota et al. Pancreatic cancer: Stroma and its current and emerging targeted therapies
JP2011079858A5 (https=)
JP2015514109A5 (https=)
ES2703826T3 (es) Inmunoterapia con IL-12 destinada al cáncer
ES2732005T3 (es) Una combinación de tetrahidrocannabinol y cannabidiol para uso para aumentar la radiosensibilidad en el tratamiento de un tumor cerebral
JP2015505843A5 (https=)
RU2016132759A (ru) Дуокармициновые adc, демонстрирующие улучшенную противоопухолевую активность in vivo
Wang et al. Emergence in protein derived nanomedicine as anticancer therapeutics: More than a tour de force
RU2018135317A (ru) Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии
JP2016528162A5 (https=)
JP2015512398A5 (https=)
Shen et al. HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma
JP2019530673A5 (https=)
JP2016530233A5 (https=)
WO2016210376A3 (en) Therapeutic peptides and methods of use thereof
Lamichhane et al. Checkpoint inhibition: will combination with radiotherapy and nanoparticle-mediated delivery improve efficacy?
WO2020018996A3 (en) Delivery of sialidase to cancer cells, immune cells and the tumor microenvironment
JP2011503039A5 (https=)
Fridlender et al. Modifying tumor-associated macrophages: An important adjunct to immunotherapy
Ge et al. Photodynamic immunotherapy using ADU-S100-modified nanoparticles to treat triple-negative breast cancer
Huang et al. Safety of lienal polypeptide injection combined with chemotherapy in treating patients with advanced cancer
Chou et al. Total gastrectomy increases the incidence of grade III and IV toxicities in patients with gastric cancer receiving adjuvant TS-1 treatment